In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery

被引:53
作者
Gordon, Sarah [1 ]
Teichmann, Elena [1 ]
Young, Katherine [1 ]
Finnie, Kim [2 ]
Rades, Thomas [1 ]
Hook, Sarah [1 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin 9054, New Zealand
[2] CeramiSphere Pty Ltd, Menai, NSW 2234, Australia
关键词
Particulate sustained release vaccine delivery system; Silica nanoparticles; Chitosan; Thermosensitive hydrogel; Immune response; CONTROLLED-RELEASE; AMORPHOUS SILICA; DRUG-DELIVERY; GEL; ADJUVANTS; CELLS; MICROPARTICLES; PARAMETERS; EXPOSURE; EMULSION;
D O I
10.1016/j.ejps.2010.07.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this work silica nanoparticles (SNP) containing the model antigen ovalbumin (OVA) were incorporated into a thermosensitive chitosan hydrogel, and the resulting formulation investigated for its potential to act as a particulate sustained release vaccine delivery system. OVA-loaded SNP and chitosan hydrogels containing OVA-loaded SNP were prepared and characterised in vitro, and examined for their ability to elicit OVA-specific immune responses in vivo. Optimised SNP were found to be approximately 300 nm in size with a moderate level of heterogeneity, a highly negative zeta potential, and an entrapment efficiency of approximately 7%. A porous particulate structure was indicated both by electron microscopy and a rapid release of fluorescently-labelled OVA (FITC-OVA) from SNP. Following successful incorporation of SNP into chitosan hydrogels, the release of both soluble and SNP-associated antigen from gel systems was quantified. Approximately 16% of total protein was released in a particulate form over a 14-day period, while approximately 35% was released as soluble antigen. Gel-based systems containing SNP-associated or soluble antigen in the presence or absence of the adjuvant Quil A (QA) demonstrated an ability to stimulate both cell mediated and humoral immunity in vivo. Chitosan gels containing OVA-loaded SNP and the adjuvant QA showed a significantly greater ability to induce CD4(+) T cell proliferation than chitosan gel containing soluble OVA and QA, indicating the future promise for such a system. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:360 / 368
页数:9
相关论文
共 42 条
[31]   Chitosan as a nonviral gene delivery system.: Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo [J].
Köping-Höggård, M ;
Tubulekas, I ;
Guan, H ;
Edwards, K ;
Nilsson, M ;
Vårum, KM ;
Artursson, P .
GENE THERAPY, 2001, 8 (14) :1108-1121
[32]   Using different structure types of microemulsions for the preparation of poly(alkylcyanoacrylate) nanoparticles by interfacial polymerization [J].
Krauel, K ;
Davies, NM ;
Hook, S ;
Rades, T .
JOURNAL OF CONTROLLED RELEASE, 2005, 106 (1-2) :76-87
[33]  
Liang Ming Tao, 2006, Current Drug Delivery, V3, P379
[34]   Immunological aspects of controlled antigen delivery [J].
Lofthouse, S .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (06) :863-870
[35]   In vivo activity of cationic immune stimulating complexes (PLUSCOMs) [J].
McBurney, Warren T. ;
Lendemans, Dirk G. ;
Myschik, Julia ;
Hennessy, Tania ;
Rades, Thomas ;
Hook, Sarah .
VACCINE, 2008, 26 (35) :4549-4556
[36]  
Myschik J, 2008, J DRUG TARGET, V16, P224, DOI [10.1080/10611860701848886, 10.1080/10611860701848886 ]
[37]   Targeting the innate immune response with improved vaccine adjuvants [J].
Pashine, A ;
Valiante, NM ;
Ulmer, JB .
NATURE MEDICINE, 2005, 11 (04) :S63-S68
[38]   RETRACTED: Surface modification for stability of nano-sized silica colloids (Retracted article, see vol 342, pg 643, 2010) [J].
Pham, Khoa N. ;
Fullston, Damian ;
Sagoe-Crentsil, Kwesi .
JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2007, 315 (01) :123-127
[39]   Safety evaluation of short-term exposure to chitooligomers from enzymic preparation [J].
Qin, CQ ;
Gao, JN ;
Wang, LS ;
Zeng, LT ;
Liu, Y .
FOOD AND CHEMICAL TOXICOLOGY, 2006, 44 (06) :855-861
[40]   In situ-forming hydrogels -: review of temperature-sensitive systems [J].
Ruel-Gariépy, E ;
Leroux, JC .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 58 (02) :409-426